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Abstract
TRPV4 is a mechanically activated Ca
2+-passing channel implicated in the sensing of forces, including those acting on bones.
To date, 33 mutations are known to affect human bone development to different extents. The spectrum of these skeletal
dysplasias (SD) ranges from dominantly inherited mild brachylomia (BO) to neonatal lethal forms of metatropic dysplasia
(MD). Complexities of the results from fluorescence and electrophysiological studies have led to questions on whether
channel activity is a good predictor of disease severity. Here we report on a systematic examination of 14 TRPV4 mutant
alleles covering the entire SD spectrum. Expressed in Xenopus oocyte and without any stimulation, the wild-type channel
had a ,1% open probability (Po) while those of most of the lethal MD channels approached 100%. All mutant channels had
higher basal open probabilities, which limited their further increase by agonist or hypotonicity. The magnitude of this
limitation revealed a clear correlation between the degree of over-activity (the molecular phenotype) and the severity of the
disease over the entire spectrum (the biological phenotype). Thus, while other factors are at play, our results are consistent
with the increased TRPV4 basal activity being a critical determinant of the severity of skeletal dysplasia. We discuss how the
channel over-activity may lead to the ‘‘gain-of-function’’ phenotype and speculate that the function of wild-type TRPV4 may
be secondary in normal bone development but crucial in an acute process such as fracture repair in the adult.
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Introduction
Mutations in the transient receptor potential cation channel
TRPV4 have been found to cause many different forms of skeletal
dysplasias (SD) [1,2,3,4,5]. These range from mild autosomal-
dominant brachyolmia (BO) [5], diagnosed by a shortened spine
with characteristic vertebral defects but only minor defects in the
long bones [6] to metatropic dysplasia (MD) [2,3,4], characterized
by more prominent spine defects as well as pronounced
abnormalities in articular skeleton resulting in short dumbbell-
shaped long bones [7], which leads to prenatal lethality in its
severest forms [8]. Clinically distinguishable spondylometaphyseal
dysplasia, Kozlowski type (SMDK) presents defects intermediate
in severity [9]. Most recently, TRPV4 mutations were also found to
cause two other clinically distinguishable SD’s: spondylo-epiphy-
seal dysplasia Maroteaux type (SDEM-PM2) and the rare
parasymetric dysplasia (PD) [1]. That TRPV4 mutation causes
SD was initially discovered through a pedigree analysis of
autosomal dominant BO patients from two familial lines followed
by position cloning [5]. Subsequent analysis of 59 genetically
diverse and mostly unrelated MD and SMDK patients found that
all but one resulted from dominant TRPV4 mutations [1,2,3,4,5].
In most cases, mutations occurred de novo, often appearing to arise
from gonadal mosaicism in the parent [10]. Four mutations in two
of the six N-terminal ankyrin repeats of TRPV4 have also recently
been shown to cause a spectrum of late-onset neuromuscular
diseases but not skeletal dysplasia [11,12,13], indicating that SD
and these neuromuscular diseases arise by different mechanisms
[14]. This report covers only the mutations causing skeletal
dysplasias and is not concerned with the four alleles causing
neuromuscular disease nor the P19S polymorphism, which loosely
correlate with serum hyponatremia [15] and chronic obstructive
pulmonary disease [16].
The mechanism by which TRPV4 mutation causes skeletal
dysplasia is unclear. TRPV4 is a polymodal Ca
2+-permeable cation
channel of 871 AA [17,18]. It shows a very prominent outward
rectification, rarely opening upon hyperpolarization. Mutational
analysis suggests that outward rectification is governed by a gating
mechanism independent of the main intracellular gate [19]. It also
shows a rectification in its unitary conductance, being 98-pS
outward and 45-pS inward [20]. Like other TRP channels, TRPV4
is polymodal, activated by mild heat [21], by the intrinsic agonists
arachidonic acid and its metabolite 59,69-epoxyeicosatrienoic acid
[22], or extrinsic agonists such as 4a-phorbol 12,13-didecanoate (4a
PDD) [23] and other phorbol derivatives [24], Bisandrographolide
[25] and GSK1016790A (GSK) [26]. TRPV4 is also regulated by
Ca
2+ [27,28], in part through calmodulin [29], as well as by other
intracellular messengers [30,31,32,33,34]. TRPV4 has been
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systemic osmolarity regulation [35], viscosity-coupled epithelial
ciliary activity [36], strain-induced endothelial cell reorientation
[37], keratinocyte cell-volume regulation [38], and load sensing of
bone [39]. Hypotonic [17,18] or shear stress [40] activates TRPV4
but the molecular mechanisms are controversial. It has been
proposed that mechanical activation was indirect, occurring
through mechanical activation of phospholipaseA2 [41]. Recently,
Loukin et al. (2010) [20] showed that TRPV4 is activated directly by
stretch force in excised membrane patches. TRPV4’s direct
molecular mechanosensitivity provides the simplest interpretation
for its roles in force-related physiologies.
While broadly expressed, TRPV4 promotes terminal differen-
tiation and inhibits apoptosis of bone-absorbing osteoclast through
aC a
2+-dependent signaling pathway [42]. Yet, in stark contrast to
the prominent pathologies caused by the mutations studied here, a
complete loss of TRPV4 activity has only minor and late-onset
effects on bone development. trpv4
2/2 knockout is not lethal and
the mice display only superficial skeletal defects. One report found
a 67% increase in density of femoral trabecula in the tomograms
of adult, but not immature trpv4
2/2 mice [42]. A concurrent
report, however, did not observe such a chronic increase in
trabecular density. Instead, trpv4
2/2 mice were found to lack
‘‘unloading osteoporosis’’, in which wild-type bones lose density
when they are deprived of the weights they normally bear [39]. In
both studies, increased osteoclast populations paralleled decreased
bone densities. In a recent report, TRPV4 knockout resulted in the
enlargement of certain joint bones consistent with osteoarthritis,
but only after 9 months and only in male mice [43].
Thirty-three unique TRPV4 mutations have been found to
cause SD to date [1,2,3,4,5]. They occur throughout the protein,
most commonly between the predicted 4th and 5th membrane-
spanning domains or near the calmodulin-binding domain in the
cytoplasmic C terminus. Whereas most of the observed mutations
occurred in only one or occasionally two cases, R594H were found
to recur in 17 and P799L in 15 unrelated individuals [1,2,3,4]. In
the initial reports the correlation between clinical severity and
genotype was absolute, with all R594H individuals having SMDK
and all P799Ls having MD. Subsequently, 2 of the 6 SDEM-PM2
cases were found to be due to P799L mutation and the sole PD
[1], which is clinically more severe than SMDK, was due to
R594H, indicating that other factors besides TRPV4 allelism can
influence disease outcome.
The molecular phenotypes of these mutant channels examined
to date are puzzling. Using Fura-2 fluorescence to gauge the Ca
2+
through TRPV4, the absolute responses to the synthetic agonist
4aPDD of I331F, P799L [3] and D333G were larger than that of
the wild type, but those of R594H and A716S were smaller [4].
The responses to the natural agonist arachidonic acid and to
hypotonicity were smaller in D333G, R594H and A716S [4].
Because it is technically demanding, direct electrophysiological
examinations were understandably sparse. Mutant alleles were
expressed in HEK293 cells and their whole-cell current registered
[3,4,5]. Basal currents were found to increase in the cases of
R616Q, V620I [5], D333G, R594H [4] I331F and P799L [3].
A716S, however, resulted in current densities indistinguishable
from those of wild type [4]. The complexity of the molecular
phenotypes as well as the fact that mutations are scattered
throughout the protein has led to questions as to whether increase
in channel activity (‘‘gain-of-function’’ molecular phenotype)
determines the disease outcome or whether a different dominant
negative mechanism may be operational [1].
Here we report on a systematic electrophysiological analysis of
14 different dysplasia-causing mutants chosen for their allelic and
clinical diversity. A strong correlation was observed between
clinical severity and an increase in the deduced basal open
probabilities. Our results are consistent with the chronic basal
open probability of the mutant TRPV4 being a key, though
probably not the only, determinant of the severity of skeletal
dysplasia in human.
Results
Mutant Channels Produce Higher Current Densities
Of the 33 unique TRPV4 mutations so far found to cause SD
[1,2,3,4,5], we chose 14 to represent different mutational locations
and to cover the entire range of clinical severity they produce. We
have shown previously that rat-TRPV4 cRNA generates a robust
microampere current in Xenopus oocytes as evidenced by its
activation by 4aPDD and hypotonicity, its blockage by ruthenium
red, and absence from a point mutant that has a disrupted channel
filter [19,20]. All 14 mutants produced large currents that retained
the strong outward rectification characteristic of wild type
channels (Fig. 1). We have shown previously that this rectification
is due to a voltage-dependent gating mechanism distinct from the
main intracellular gate, which responds to mechanical and
chemical stimulation [19]. This second gating mechanism is
apparently not significantly affected by any of the mutations here.
Activation upon depolarization and deactivation upon repolariza-
tion of the mutants appeared similar to those of the wild type.
Whereas wild-type channels partially inactivate during depolar-
ization (Fig. 1, wild type), most mutants, particularly ones that
caused more severe clinical phenotypes, lacked such inactivation
(e.g. compare R616Q and V620I in Fig. 1, which cause the milder
BO, to I604M and L618P, which cause neonatal lethal MD). This
loss of inactivation is likely a symptom of main-gate malfunction
and has been observed in gain-of-function rat-TRPV4 mutants,
selected after random mutageneses for their inhibition of yeast
growth [19].
Although most mutants generated unstimulated ensemble
current levels, normalized to the amount of cRNA injected, larger
than those of wild type on average (Fig. 2), we encountered large
variations, sometimes of greater than 50 fold (Fig. 2). This large in-
group variance makes uncertain the comparisons between mutant
groups. Thus, we were unable to distinguish any correlation
between the severity of disease and simply the raw mutant basal
currents observed here. We have previously observed such
variability with TRPV4 expressed in oocytes [20]. Its source
could include natural oocyte-to-oocyte variation or uncontrolled
variance in the actual amount of full-length cRNA injected. More
importantly, we suspect that a negative feedback may limit current
density in such a way that toxicity of channel expression triggers a
down regulation particularly in the case of the stronger mutants
(see Discussion).
The Loss of Response to Stimulation Parallels the Clinical
Severity of the Mutants
As a way to sidestep the variation in the absolute current
magnitude, the relative change of each current after stimulation was
examined. In contrast to basal current densities, a clear negative
correlation was apparent between clinical severity and relative
response to stimulus of the corresponding mutant channel. A 100
mOsM hypotonic down-shift (350 to 250 mOsm) in the bath
caused a saturable increase in wild-type currents over the course of
a few minutes (Fig. 3a). This current is reversible upon return to
isotonicity and is blocked by ruthenium red [19,20]. L618P, which
causes the most severe neonatal-lethal form of MD, almost
completely lacked a response (Fig. 3b). The small decrease here
TRPV4 Activity Correlates with Skeletal Dysplasia
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the mutant responses were consistently smaller (Fig. 3c). This
decrease clearly correlated with disease severity, particularly
apparent when viewed from the perspective of disease-type
average (Fig. 3d). Hypotonicity triggered on average a 130%
increase in the currents from mutants that cause the mildest form,
BO (Fig. 3d). In contrast, it triggered less than a 30% average
increase in those that cause the moderate or severe MD (Fig. 3d,
right), and most of that increase was due to a single outlier, T89I
(Fig. 3c, right group). Of the 4 alleles that cause lethality, F471D,
I604M and L618P essentially did not respond to hypotonicity
(Fig. 3 b, c).
Even more pronounced is the negative correlation between the
clinical severity and the mutant channel’s response to a synthetic
agonist. GSK1016790A (‘‘GSK’’) is a strong TRPV4-specific
agonist that is more potent than 4aPDD by several hundred folds
[26]. The application of this powerful agonist, unlike the more
natural hypotonic stimulus, appear to drive the channel to its
activity maximum (See below). Outward currents from oocytes
expressing wild-type TRPV4 increase on average 80 fold over the
course of a few minutes in response to GSK (Fig. 4a, c left). Again,
with the exception of T89I, the lethal alleles had almost no
response to even this extremely potent agonist (Fig. 4b, c right
group). The mildest BO-inducing mutants gave a ,50% increase,
while the SMDK- and milder-MD-causing mutants gave about
20% increase (Figs. 4c, d). Thus, the reduction in the GSK-
induced fraction of the mutant channels robustly parallels the
clinical severity of the disease to an even greater extent than in the
case of hypotonicity.
Lack of Stimulus Response is Due to Higher Basal Open
Probability
In a previous report [20], we described the single-channel
activities of the BO-causing R616Q TRPV4 under patch clamp.
R616Q channel retains its conduction, filtration, rectification, and
mechanosensitivity property, but has a clearly increase Po even
without any stimulation. An increased basal Po leaves less room
for its rise to the maximum. This ‘‘ceiling’’ effect seems an obvious
reason that underlies the reduced responses of the mutant
TRPV4s to hypotonicity or GSK described above (Fig. 3).
Although a complete patch-clamp examination of all the mutants
is impractical because of the time and labor required, we did test a
second and stronger mutant allele: the lethal I604M. The basal Po
of wild-type TRPV4 is so low that patches containing only a single
Figure 1. All fourteen mutant TRPV4 cRNAs tested generated robust currents in Xenopus oocytes. Two to four days after the injection of
22 ng of wild-type or lesser amounts of mutant cRNAs, oocytes were examined with a two-electrode voltage clamp, held at 260 mV and tested every
5 sec between 2100 and +60 mV for 1 sec. All mutants retained strong rectification against steady-state inward current. See text. All calibration bars
are 4 mA60.2 sec.
doi:10.1371/journal.pone.0019533.g001
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stimulus (Fig. 4a, left). Upon application of GSK, the Po rapidly
approached 100% (Fig. 4a, right), consistent with the pronounced
80-fold increase of the wild-type ensemble currents (Fig. 4c, d). In
contrast, I604M had a Po near 100% even before GSK exposure
and therefore showed only a little increase after (Fig. 4b, note that
sporadic spiky closures became less prevalent after treatment).
Thus the decrease of the mutants’ response to stimuli (Figs. 3, 4)
reflects a ceiling effect, not a reduced sensitivity to stimuli.
Furthermore, the observation that GSK opened the wild-type
channel completely allows inference from the inverse of the
ensemble GSK-activated responses (See Discusion).
Discussion
In single-channel analysis, R616Q, which causes the mild
brachyolmia, has an increase in basal open probability (Po)
compared to wild type [20], but not nearly strong as that of the
lethal I604M which has a Po near 1.0 (Fig. 5), directly
demonstrating a correlation between basal open probability and
resulting clinical severity of the products of these three alleles.
Because it is labor intensive to obtain patch-clamp data from all 14
mutants, we deduced the basal Po’s of the remaining mutants
using two electrode voltage clamp (TEVC). Since little consistent
allelic difference was observed in the unstimulated basal currents
of oocytes incubated for 3 to 4 days (see a discussion of this below)
we instead relied on an analysis of a ‘‘ceiling effect’’ using
GSK1016790A. The near lack of response of I604M to GSK in
TEVC (Fig. 4) is clearly due to its observed near 100% initial Po
(Fig. 5b). The dramatic GSK response of wild-type in TEVC
(Fig. 4) clearly results from its low initial Po coupled with GSK’s
ability to completely open the channel (Fig. 5a) and the reduced
response of the milder R616Q (Fig. 4) is consistent with its
increased unitary Po observed previously [20]. We are therefore
confident that the ceiling effect in the TEVC response to GSK can
likewise be used to determine initial unstimulated Po’s of the
remaining mutants. Another advantage of using the ceiling effect
as opposed to basal current densities is that it provides a clear
internal control for each oocyte against differences in expression
levels, since GSK opens the channels to unity, and therefore basal
Po can simply be deduced from the inverse of the relative
stimulation by GSK. Such analysis reveals that wild type channels
have initial Po’s of ,1% (1/80-fold average stimulation), BO-type
channels averaging ,2% (1/44), SMDK and mild to moderate
MD ,5% (1/18), and severe and lethal MD nearly 40% (1/2.4),
with 3 of the 4 lethal alleles having basal Po’s near 100%. A robust
correlation clearly exists between basal Po and disease severity.
The Po increase explains the mutants’ dominance over wild type
in causing disease as evidenced by the fact that all subjects
examined were heterozygous at the TRPV4 locus.
Because the14 alleles studied here were chosen to represent the
distribution of the mutations in the protein and cover the entire
SD-disease spectrum, it seems reasonable to assume that all 33
known SD-causing alleles have increased basal open probabilities.
Such increases in constitutive activity are well known to result in
the ‘‘gain-of-function’’ (GOF) biological phenotypes in other TRP
channels. E.g. TRPC1 GOF mutations cause retinal degeneration
in fly [44], TRPML3 GOFs caused developmental defects of the
veritint-waddler mouse [45,46]. GOFs of TRPV1 [47], TRPV4
[19] and TRPY1 [48] have also been selected through their ability
to stop yeast growth. The common mechanism is likely the
cytotoxic effect of Ca
2+ entered through constitutively open
channels.
Our conclusion that all SD-causing mutations are GOFs largely
agrees with previous findings. Larger ensemble currents were
found in 2 BO- [5], 2 SMDK- [4] and 2 MD-causing mutants [3],
though not in the SMDK-causing A716S [4]. Here, we found
A716S channel to also be overly active (Fig. 1, 2), particularly
when assessed by its muted hypotonic or GSK response (Fig. 3, 4).
The origin of the discrepancy is unclear and is not easy to sort out
because different heterologous expressions (in HEK293 cells vs.
oocyte) were used. We note that, in the previous study, the Ca
2+-
dependent Fura-2 fluorescence did not increase in the case of
R594H and A716S, hinting at a ceiling effect [4], similar to what
we observed here.
It is puzzling that a clearer difference between the basal current
densities of the BO and the lethal channels shown in Fig. 2 did not
stand out against the statistical errors. One simple explanation is
that a homeostatic mechanism was at play that down-regulated the
stronger GOF channels, possibly by activating a retrieval or
degradation pathway in response to deleterious channel activity,
perhaps through the Ca
2+ that leaks in. Consistent with this
interpretation, we observed that large current densities of over
5 mA at 60 mV could often be observed from the many mutants
after only 24 hours after injection, and current densities generally
did not increase beyond 2 days incubation. mA currents from wild-
type were never observed before 3 days of incubation despite the
fact that its cRNA was injected at ,10-fold higher concentration
(22 ng as opposed to 1–4 ng for the mutants), and current densities
increased up to 5 days after injection. In retrospect, if currents
were all collected from oocytes expressing TRPV4’s for only
24 hours instead of between 72 and 96 hours as had mostly been
done in these experiments, then a direct correlation between
clinical severity and basal current density may well have been
observed. Toxicity of TRPV4 GOF mutations to oocytes has
previously been shown [19]. Our experience therefore cautions the
Figure 2. Basal current densities of oocytes expressing TRPV4
mutant channels are greater than those of wild type but highly
variable. Peak currents at +60 mV from oocytes expressing wild type
or mutant TRPV4 assessed between 72 and 96 hours after cRNA
injection were measured and standardized to the amount of cRNA
injected (triangles plotted on a log scale because of the large range,
mean 6 s.e.m.). Alleles are grouped by the severity of disease they
cause. ‘‘WT’’ denotes wild-type and disease abbreviations are described
in the text. MD mutants are further subdivided into mild, moderate
(‘‘mod’’), severe (‘‘sev’’) and infantile/neonatal lethal (‘‘lethal’’) as
described in Camacho et al. (2010) [3]. Whereas the expression of the
more severe mutants often reached peak within 24 hours, those of
weaker alleles generally took longer and unstimulated wild-type
currents were usually not apparent until 72 hours after injection.
doi:10.1371/journal.pone.0019533.g002
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GOF mutants, at least with oocytes.
Our own data are also not without some complexity. Among the
neonatal-lethal alleles tested, T89I consistently had a larger
response to both hypotonicity and GSK (Figs. 3, 4) than F471D,
I604M and L618P, the other lethal mutants. While most
mutations tested here are predicted to be in the membrane-
embedded domain, T89I is at the far N-terminal end, ahead of the
ankyrin repeats in the cytoplasm. It seems possible that the
pathology T89I induces may include additional mechanisms such
as membrane trafficking, beside simple constitutive activities. The
GSK responses of the mutants that caused the mildest forms of
MD were statistically indistinguishable from those that caused
SMDK (Fig. 4d). This does not reflect sampling noise, as
evidenced by the fact that E797K and particularly R594H have
been recurrently found to cause MD and SMDK respectively, yet
have nearly identical GSK responses. Here, disease distinction
must be influenced by other facets of TRPV4 activity besides basal
current level alone.
The recent finding that R594H can cause the much more severe
PD syndrome and that P799L causes SDEM-PM2 has led to the
conclusion that the genotype-phenotype correlations are not
robust [1]. While there are indeed exceptions, genotypes do
appear as a whole to correlate well with disease diagnosis.
Although two P799L cases were reported to have SDEM-PM2 [1],
the other fourteen P799L cases and four other P799X cases were
all diagnosed to have MD [2,3,4] and not other forms of dysplasia.
Besides the lone case of a single PD patient the remaining sixteen
reported R594H cases were all classified as SMDK or SMDK-like
[2,4]. Also, two cases each of F471D, R775K, E278K and E797K
were consistently classified, as were I133T/F cases [2,3,4]. While
there is not an absolute correlation, the molecular defects to
TRPV4 are clearly the major determinant of disease outcome.
How could the over-activity of TRPV4 lead to developmental
defects in skeletal development? TRPV4 participates in the
terminal differentiation of developing osteoclasts by providing a
sustained Ca
2+ influx [42]. This Ca
2+ results the nuclear
translocation of NFATc1 (nuclear factor-activated T cell c1),
which promotes the expression osteoclast-specific genes, and
possibly also in a blockage of apoptosis. As reviewed in the
Introduction, two concurrent studies indicated that trpv4
2/2 mice
had decreased osteoclast populations that coincided with increase
in bone densities, although this was only observed in response to
chronic unloading in one study [39,42]. If loss of TRPV4 function
can lead to a decrease in the bone-absorbing osteoclasts and
therefore a subtle increase in bone density, one might predict that
GOF mutations could have the opposite effect of increasing
osteoclast proliferation during development and resulting in
Figure 3. Mutant channels have limited hypotonic responses that inversely correlate with clinical severity. a. Currents were monitored
from an oocyte expressing wild-type TRPV4 with 250 ms depolarizations to +40 mV from a hold of 0 mV every 10 s after the removal of 100 mM
sorbitol from the media (left, with serial depolarizations vertically stacked). Peak currents from serial depolarizations are plotted against hypotonic
exposure time on right. Vertical current scale for both raw traces and plot is shown on right. b. Same as in a, except that oocyte is expressing the
neonatal-lethal allele L618P and the test potential was +30 mV. c. Relative increases in peak currents caused by hypotonicity from oocytes expressing
wild type and mutant TRPV4 channels assessed at +60 mV. Alleles are grouped by the severity of the dysplasia they cause as described in Fig. 2
legend. Triangles represent individual data points from unique oocytes, vertical bars are the allele means, and error bars are the standard error within
each allele. d. Average of the individual allele average hypotonic responses grouped by clinical severity, with error bars representing the s.e.m. of the
allele averages. ‘‘m/m MD’’ represents mild and moderate MD, whereas ‘‘s/l’’ represents severe and lethal. Whereas the clinically mildest BO mutants
only have a moderate reduction in their response to hypotonicity, most of the severest MD mutants have little or no response.
doi:10.1371/journal.pone.0019533.g003
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vertebrae, brachydactyly, delayed carpal ossification, shortened
trunk and limbs, facial hyperplasia, etc.
Given the dramatic effects GOF mutations has on bone
development, it seems paradoxical that trpv4
2/2 mice develop
normal skeletons at birth [39,42]. Even the chronically increased
bone density, when observed, was not in immature trpv4
2/2 mice
but only in adults and with no change in overall bone dimension
[42]. Therefore, even though TRPV4 is expressed in chondrocytes
[43,49,50] and osteoclasts, the knock-out phenotypes indicate that
TRPV4 channel only plays a redundant, auxiliary, or amplifica-
tion role in embryonic bone development [39,42]. While TRPV4
Figure 4. The limitation of the very large GSK responses shows an even more pronounced negative correlation with disease
severity. Responses to 1 mM GSK are shown. All figures are arranged as in Fig. 3. Note the near 100-fold increase of the wild-type current here (a, c,
d) as compared to the ,10-fold increase by hypotonicity. As with hypotonicity, the majority of the most severe mutants have little or no response to
GSK (b, c, d).
doi:10.1371/journal.pone.0019533.g004
Figure 5. Single channel analysis confirms that lack of response to stimuli is due to saturated basal open probability in I604M.
Excised patches with single active channels were analyzed from oocytes expressing either wild-type cRNA (a, n.100) or the neonatal-lethal allele
I604M (b, n=3). Shown are outward unitary currents at +50 mV before (left) and after (right) brief exposure to 1 mM GSK. Open (o) and closed (c)
current levels are marked. 50-fold time expansions are shown in B to confirm that the downward spikes indeed reflect the rare full channel closure as
evidenced by occasional brief plateaus at the fully closed level (*).
doi:10.1371/journal.pone.0019533.g005
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is not a selectable trait during evolution, since animals with
weakened bones should have a disadvantage. A tempting
speculation is that TRPV4 may instead be involved in an acute
bone development response such as fracture repair in the adult.
Osteoclasts are known to chemotax to areas of microfracture [51]
and play a key role in the final stage of fracture repair, the
remodeling of the woven hard callus into the original cortical and/
or trabecular bone configuration [52]. TRPV4-mediated osteo-
clast proliferation may be crucial in this remodeling. TRPV4
activation by mechanical stress could facilitate osteoclast develop-
ment to the point that the remodeled mature bone relieves this
stress. Bone fracture is common in adult vertebrates and early
humans. An efficient repair mechanism should be an evolved trait.
To our knowledge, fracture healing in trpv4




Wild-type rat TRPV4 was integrated into pGH19 vector as
described elsewhere [19]. GOF mutations were introduced by a
standard 2-step PCR protocol using high-fidelity PfuUltra
polymerase (Stragene) and reintegrated into pGH19. cRNA was
synthesized from Xho1-linearized templates using a mMessage
mMachine T7 kit (Ambion). Stage V and VI X. laevis oocytes were
each injected with between 1 and 22 ng of cRNA. Channel
activities of the stronger GOF mutants appeared and reached near
maximum within 24 hours and could be analyzed over the course
of several days. Unstimulated wild-type currents were generally
not apparent until three days post injection, and the majority of
basal and hypotonically stimulated wild-type currents were
recorded at or after this point. For the wild-type GSK
experiments, it was necessary to use oocytes expressing for only
2 days, since it was critical to only use oocytes with basal currents
between 100 and 500 nA at 60 mV, levels high enough to
quantitate before GSK exposure but were not subsequently too
large for recording conditions after exposure. Since TRPV4
expression, particularly of GOF alleles is toxic to oocytes [19],
1 mM ruthenium red (Sigma) was added to the ND96 incubation
buffer. Oocytes were rinsed in ruthenium-free solutions before
recording.
Two Electrode Voltage Clamp (TEVC)
TEVC recording used HS2A head stages and a VG-2Ax100
virtual bath clamp connected to a Gene Clamp 500 amplifier
interfaced through a Digidata 1440A digitizer acquired using
pClamp10 software (all Axon Instruments). The base bath solution
contained (in mM) 66 K
+-methanosulfate, 100 sorbitol, 1.8
Ba(OH)2, and 5 K
+-HEPES, pH 7.2 (all Sigma). All solutions
were maintained under continuous perfusion at a rate of ,2 mls/
min. Sorbitol was omitted from the base solution to form the
hypotonic solution. Data was acquired using pClamp10 (Axon
Instruments) and analyzed using this as well as Sigma Plot 2000
(SPSS) software and Origin 8.1 (OriginLab). Simultaneously
measured membrane voltages showed that they could lag the
command voltage by over 5 mV when large currents were
maintained. To account for this, linear fits between the measured
voltages at +40 and +60 mV commands were always used to
extrapolate the values predicted at +60 mV for Figs. 2, 3c and 4c.
Leak subtraction was not necessary nor used in any of the TEVC
analyses.
Patch Clamp Analysis
Patch clamp recordings used an L/M EPC7 amplifier (List
Medical) interfaced through a Digidata 1440A digitizer using
pClamp10 software (both Axon Instruments). Data was acquired
at 10 kHz through an eight-pole Bessel filter at 1 kHz, played back
at .5 kHz for analysis using pClamp10 software. Borosilicate
glass pipettes with ,1-mm diameter opening at the tip were used.
Recordings were done in excised inside-out mode in symmetric (in
mM) 98 KCl, 1 MgCl2,a d1 0K
+-HEPES, pH 7.2 (all Sigma).
1 mM GSK was added directly to the bath when tested.
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